Passage Bio, Inc. – NASDAQ:PASG

Passage Bio stock price today

$6.53
+5.87
+893.91%
Financial Health
0
1
2
3
4
5
6
7
8
9

Passage Bio stock price monthly change

-30.11%
month

Passage Bio stock price quarterly change

-30.11%
quarter

Passage Bio stock price yearly change

-30.28%
year

Passage Bio key metrics

Market Cap
39.53M
Enterprise value
49.11M
P/E
-0.48
EV/Sales
N/A
EV/EBITDA
-0.37
Price/Sales
N/A
Price/Book
0.28
PEG ratio
-0.01
EPS
-1.54
Revenue
N/A
EBITDA
-88.94M
Income
-84.43M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Passage Bio stock price history

Passage Bio stock forecast

Passage Bio financial statements

Passage Bio, Inc. (NASDAQ:PASG): Profit margin
Jun 2023 0 -23.85M
Sep 2023 0 -27.11M
Dec 2023 5.91M -16.75M -283.46%
Mar 2024 0 -16.71M
Passage Bio, Inc. (NASDAQ:PASG): Analyst Estimates
Dec 2023 5.91M -16.75M -283.46%
Mar 2024 0 -16.71M
Oct 2025 0 -10.13M
Dec 2025 0 -10.13M
  • Analysts Price target

  • Financials & Ratios estimates

Passage Bio, Inc. (NASDAQ:PASG): Debt to assets
Jun 2023 193696000 43.28M 22.35%
Sep 2023 169256000 42.98M 25.39%
Dec 2023 150545000 39.26M 26.08%
Mar 2024 140531000 35.64M 25.37%
Passage Bio, Inc. (NASDAQ:PASG): Cash Flow
Jun 2023 -17.13M 13.96M 89K
Sep 2023 -19.16M 22.45M 0
Dec 2023 -19.51M 7.6M 46K
Mar 2024 -18.92M 25.25M 8.74M

Passage Bio alternative data

Passage Bio, Inc. (NASDAQ:PASG): Employee count
Aug 2023 85
Sep 2023 85
Oct 2023 85
Nov 2023 85
Dec 2023 85
Jan 2024 85
Feb 2024 85
Mar 2024 58
Apr 2024 58
May 2024 58
Jun 2024 58
Jul 2024 58

Passage Bio other data

69.79% -5.85%
of PASG is owned by hedge funds
37.95M -3.09M
shares is hold by hedge funds

Passage Bio, Inc. (NASDAQ:PASG): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 42298
Feb 2024 0 3108
Sep 2024 0 239431
Nov 2024 456353 0
Dec 2024 0 389700
Transaction Date Insider Security Shares Price per share Total value Source
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 230,321 $0.6 $138,193
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 80 $0.8 $64
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 8,015 $0.8 $6,412
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 54,181 $0.84 $45,512
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 20,903 $0.82 $17,140
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 76,200 $0.79 $60,198
Purchase
LYNX1 CAPITAL MANAGEMENT LP 10 percent owner
Common Stock 29,300 $0.67 $19,660
Purchase
LYNX1 CAPITAL MANAGEMENT LP 10 percent owner
Common Stock 167,055 $0.71 $118,275
Purchase
LYNX1 CAPITAL MANAGEMENT LP 10 percent owner
Common stock, $0.0001 par value per share ("Common Stock") 259,998 $0.56 $146,639
Sale
ORBIMED ADVISORS LLC 10 percent owner
Common Stock 39,300 $0.71 $27,903
Insider Compensation
Dr. Bruce A. Goldsmith M.B.A., Ph.D. (1966) Chief Executive Officer, Pres & Director
$756,920
Friday, 29 November 2024
https://thefly.com
Wednesday, 6 November 2024
globenewswire.com
Thursday, 24 October 2024
globenewswire.com
Monday, 23 September 2024
globenewswire.com
Tuesday, 10 September 2024
globenewswire.com
Friday, 30 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Tuesday, 16 July 2024
globenewswire.com
Tuesday, 18 June 2024
zacks.com
Wednesday, 5 June 2024
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 16 May 2024
zacks.com
Tuesday, 14 May 2024
globenewswire.com
Monday, 22 April 2024
GlobeNewsWire
Thursday, 7 March 2024
Zacks Investment Research
Tuesday, 27 February 2024
GlobeNewsWire
Thursday, 1 February 2024
InvestorPlace
Wednesday, 31 January 2024
GlobeNewsWire
Monday, 25 December 2023
InvestorPlace
Monday, 30 October 2023
GlobeNewsWire
Monday, 25 September 2023
GlobeNewsWire
Tuesday, 1 August 2023
GlobeNewsWire
Monday, 5 June 2023
GlobeNewsWire
Monday, 17 April 2023
GlobeNewsWire
Monday, 27 March 2023
GlobeNewsWire
Monday, 6 March 2023
Seeking Alpha
Tuesday, 28 February 2023
Seeking Alpha
Monday, 27 February 2023
GlobeNewsWire
Wednesday, 15 February 2023
GlobeNewsWire
  • What's the price of Passage Bio stock today?

    One share of Passage Bio stock can currently be purchased for approximately $6.53.

  • When is Passage Bio's next earnings date?

    Unfortunately, Passage Bio's (PASG) next earnings date is currently unknown.

  • Does Passage Bio pay dividends?

    No, Passage Bio does not pay dividends.

  • How much money does Passage Bio make?

    Passage Bio has a market capitalization of 39.53M.

  • What is Passage Bio's stock symbol?

    Passage Bio, Inc. is traded on the NASDAQ under the ticker symbol "PASG".

  • What is Passage Bio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Passage Bio?

    Shares of Passage Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Passage Bio's key executives?

    Passage Bio's management team includes the following people:

    • Dr. Bruce A. Goldsmith M.B.A., Ph.D. Chief Executive Officer, Pres & Director(age: 59, pay: $756,920)
  • How many employees does Passage Bio have?

    As Jul 2024, Passage Bio employs 58 workers.

  • When Passage Bio went public?

    Passage Bio, Inc. is publicly traded company for more then 5 years since IPO on 28 Feb 2020.

  • What is Passage Bio's official website?

    The official website for Passage Bio is passagebio.com.

  • Where are Passage Bio's headquarters?

    Passage Bio is headquartered at One Commerce Square, Philadelphia, PA.

  • How can i contact Passage Bio?

    Passage Bio's mailing address is One Commerce Square, Philadelphia, PA and company can be reached via phone at +267 8660311.

Passage Bio company profile:

Passage Bio, Inc.

passagebio.com
Exchange:

NASDAQ

Full time employees:

58

Industry:

Biotechnology

Sector:

Healthcare

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

One Commerce Square
Philadelphia, PA 19103

CIK: 0001787297
ISIN: US7027121000
CUSIP: 702712100